Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

被引:129
作者
Thiele, Juergen [1 ]
Kvasnicka, Hans Michael [1 ]
Muellauer, Leonhard [2 ]
Buxhofer-Ausch, Veronika [3 ]
Gisslinger, Bettina [3 ]
Gisslinger, Heinz [3 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Med Univ Vienna, Inst Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; WORLD-HEALTH-ORGANIZATION; BONE-MARROW BIOPSY; CHRONIC MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA-VERA; DIAGNOSTIC-CRITERIA; INTEROBSERVER RELIABILITY; DIFFERENTIAL-DIAGNOSIS; PROGNOSTIC-FACTORS; NEOPLASMS;
D O I
10.1182/blood-2010-07-293761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofibrosis (PMF) presenting with thrombocythemia. To investigate the impact and reproducibility of bone marrow (BM) morphology according to the World Health Organization classification, 295 patients with the presumptive clinical diagnosis of either ET or early PMF were studied. Data of this cohort (Vienna group) were compared with 732 corresponding patients (Cologne group). Evaluating blindly (only age and gender known) BM specimens, the 2 groups of pathologists achieved an overall consensus of 78% regarding the total series and 88% concerning the discrimination between ET versus PMF. In 126 ET and 81 early PMF patients without pretreatment and complete documentation, a 90% concordance with the independently established clinical diagnosis was found. In 12 patients, overlapping of histopathology and some clinical findings between ET and polycythemia vera occurred. Contrasting ET, early PMF showed significant differences of presenting hematologic data and an unfavorable prognosis (estimated mean survival, 14 vs 21 years). Comparison of clinical and survival data of the Vienna cohort with the historical Cologne series revealed an overall congruence. This study highlights the impact of BM morphology for the differentiation between true vs false ET. (Blood. 2011; 117(21): 5710-5718)
引用
收藏
页码:5710 / 5718
页数:9
相关论文
共 44 条
[1]  
BARBUI T, J CLIN ONCO IN PRESS
[2]  
BAUERMEISTER DE, 1971, AM J CLIN PATHOL, V56, P24
[3]   Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms [J].
Boiocchi, Leonardo ;
Vener, Claudia ;
Savi, Federica ;
Bonoldi, Emanuela ;
Moro, Alessia ;
Fracchiolla, Nicola Stefano ;
Iurlo, Alessandra ;
Deliliers, Giorgio Lambertenghi ;
Coggi, Guido ;
Bosari, Silvano ;
Gianelli, Umberto .
JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (03) :226-231
[4]   Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis [J].
Brousseau, Maud ;
Parot-Schinkel, Elsa ;
Moles, Marie-Pierre ;
Boyer, Francoise ;
Hunault, Mathilde ;
Rousselet, Marie-Christine .
HISTOPATHOLOGY, 2010, 56 (06) :758-767
[5]   MYELOFIBROSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS - INCIDENCE AMONG SUBTYPES ACCORDING TO THE HANNOVER CLASSIFICATION [J].
BUHR, T ;
GEORGII, A ;
CHORITZ, H .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (02) :121-132
[6]   Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens [J].
Buhr, T ;
Büsche, G ;
Choritz, H ;
Länger, F ;
Kreipe, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (01) :152-158
[7]   Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy [J].
Campbell, Peter J. ;
Bareford, David ;
Erber, Wendy N. ;
Wilkins, Bridget S. ;
Wright, Penny ;
Buck, Georgina ;
Wheatley, Keith ;
Harrison, Claire N. ;
Green, Anthony R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2991-2999
[8]   Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia [J].
Chim, CS ;
Kwong, YL ;
Lie, AKW ;
Ma, SK ;
Chan, CC ;
Wong, LG ;
Kho, BCS ;
Lee, HK ;
Sim, JPY ;
Chan, CHN ;
Chan, JCW ;
Yeung, YM ;
Law, M ;
Liang, R .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) :2651-2658
[9]  
Florena AM, 2004, HAEMATOLOGICA, V89, P911
[10]   The histopathology of chronic myeloproliferative diseases [J].
Georgii, A ;
Buesche, G ;
Kreft, A .
BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (04) :721-749